M&A strategies in our business are hit and miss," said Eric Schmidt, managing director and senior research analyst at Cowen & Co., in New York

Kythera Biopharmaceuticals Inc., of New York, reported that MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF), commonly known as double chin, during an oral session at the Aesthetic Meeting 2013 in New York

Bristol-Myers Squibb Co., of New York, named Francis Cuss executive vice president and chief scientific officer, effective July 1

a steroid nucleus-based mineralocorticoid receptor antagonist Myocardial infarction The trial showed a 42.9% relative risk reduction in the primary endpoint 3/12/13 Pfizer Inc. (New York) Prevnar 13 Pneumococcal 13-valent conjugate vaccine HIV Phase III data demonstrated immunogenicity, tolerability and safety 3/6/13 Pfizer Inc. (New York) Xeljanz Tofacitinib citrate Rheumatoid arthritis Japanese regulators approved it 3/27/13 Phosphagenics Ltd. (Melbourne, Australia) Oxymorphone Patch Pain

New York) Uplyso Alfataliglicerase Gaucher disease Received regulatory approval in Brazil 3/19/13 Prothena Corp

New York) OHR/AVR118 Anti-inflammatory drug Advanced cancer with cachexia Phase II trial did not meet the primary endpoint of weight gain, but the 18 patients who completed treatment achieved stable body weight, body fat and muscle mass with a significant increase in appetite 3/22/13 Oncolytics Biotech Inc. (Calgary, Alberta) Reolysin Intravenous therapy Non-small-cell lung cancer...New York) Ad-RTS IL-12 Previously ZIN ATI-001 Nonresectable recurrent or metastatic breast cancer Started a Phase II

Bristol-Myers Squibb Co., of New York, will invest $250 million to expand its large-scale biologics manufacturing facility in Devens, Mass., introducing biologics development and clinical trial manufacturing capabilities and adding about 350 employees

New York) Palifosfamide Alkylating agent Metastatic soft tissue sarcoma Failed to meet the primary endpoint of progression-free survival 3/27/13 CARDIOVASCULAR Acasti Pharma Inc. (Laval, Quebec) NKPL66 CaPre Mild-to-high hypertriglyceridemia Preliminary data showed it achieved a statistically significant triglyceride reduction of up to 23%, compared to standard of care, after four weeks of treatment 3/20/13 Biogen Idec Inc. (Cambridge, Mass.) rRIXFc Recombinant factor IX Fc fusion protein

the drug also met a key secondary endpoint 3/22/13 Biotie Therapies Corp. (Turku, Finland) SYN115 Tozadenant Parkinson's disease Phase IIb data showed significant reductions in mean placebo-corrected change from baseline in "off" time were observed with tozadenant 120 mg BID and 180 mg BID 3/22/13 BrainStorm Cell Therapeutics Inc. (New York) NurOwn Technology for the propagation and differentiation of autologous mesenchymal stem cells into nuerotrophic factor-secreting cells Amyotrophic lateral

A partnership between Roche AG and Chiasma Inc., of New York, could generate a total of $595 million

In 2007, dalbavancin, which was then owned by New York-based Pfizer Inc. (acquired in the Vicuron Pharmaceuticals Inc. buyout of 2005), got snagged in the FDA's shifting guidelines on antibiotic development, earning a rejection despite hitting its endpoint in an 800-patient noninferiority trial in skin infections

Secondary objectives are safety and tolerability, dyspnea, fluid overload, blood pressure, diuretic dose and New York Heart Association classification

Synergy Pharmaceuticals Inc., of New York, will boost its development of plecanatide, a candidate for gastrointestinal disorders, with an offering of $90 million of common stock

Pfizer Inc., of New York, said its palbociclib (PD-0332991), an oral and selective inhibitor of cyclin-dependent kinases 4 and 6, received breakthrough therapy designation by the FDA for the potential treatment of patients with breast cancer

WASHINGTON– As far as cellular processes go, mitosis seems like a natural target for cancer drugs. "Its major business is cell growth," Genentech Inc.'s Peter Jackson told the audience at the annual meeting of the American Association for Cancer Research (AACR). It's got kinases – lots of kinases. And there is a "vast array" of traditional chemotherapies that hits some aspect of the cell cycle. But to date, clinical results of inhibiting cell cycle progression have been less successful than the

It's website, though, still prominently notes, "We are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching $261 million...One involved a financial software company (Longtop Financial Technologies Ltd.) that was delisted by the New York Stock Exchange in August 2011

It's website, though, still prominently notes, "We are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching $261 million...One involved a financial software company (Longtop Financial Technologies Ltd.) that was delisted by the New York Stock Exchange in August 2011

Stemline Therapeutics Inc., of New York, said an ongoing collaboration with the Dana-Farber Cancer Institute featuring SL-401, currently in late-stage testing for hematological malignancies such as blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia, has shown activity in an additional hematologic malignancy, multiple myeloma, in preclinical models

NYSE = New York Stock Exchange